Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 161
Filtrar
3.
Minerva Pediatr ; 63(3): 233-5, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21654603

RESUMO

Neonatal pulmonary hypertension refractory to high frequency ventilation (HFOV) and inhaled nitric oxide (iNO) is an occasional occurrence. We report a full-term neonate with severe pulmonary hypertension unresponsive to the treatment with HFOV and iNO, later associated with prostacyclin, who rapidly improved after the addition of vecuronium, a neuromuscular blocker.


Assuntos
Bloqueio Neuromuscular , Síndrome da Persistência do Padrão de Circulação Fetal/terapia , Administração por Inalação , Anti-Hipertensivos/uso terapêutico , Epoprostenol/uso terapêutico , Feminino , Humanos , Recém-Nascido , Óxido Nítrico/administração & dosagem , Síndrome da Persistência do Padrão de Circulação Fetal/tratamento farmacológico , Falha de Tratamento
4.
Eur J Cancer ; 47(4): 491-5, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21247756

RESUMO

Palliative care and palliative medicine define a relatively new medical discipline that has arisen in response to the need for better approaches to caring for people with advanced life-limiting illnesses. For professional, managerial and cultural reasons, it has evolved largely outside of academic structures. As the discipline has matured, its needs for education, training, intellectual discourse, evidence development and new science have become more apparent. Traditional academia remains sceptical about the role of palliative medicine, and bastions of palliative medicine expertise in universities have been slow to develop. Yet the engagement of the academic sector in palliative medicine has distinct benefits: (1) promoting the exploration of the culture, humanities and science of the discipline; (2) generating evidence to support practice; (3) creating a legion of educators to train a palliative medicine workforce and to inform clinical colleagues of the role of palliative medicine; and (4) providing order and direction to the discipline's development. A roadmap leading to better engagement between palliative medicine and academia is needed. Examples of developments that could help bridge the two domains include: standardisation of terminology and clarification of boundaries of influence; focus on high-quality research that will generate robust evidence to support clinical decision-making; and clear definition of outcomes, with measures that are understandable across medical disciplines.


Assuntos
Cuidados Paliativos/organização & administração , Docentes de Medicina , Humanos , Cuidados Paliativos/tendências , Sistemas Automatizados de Assistência Junto ao Leito , Assistência Terminal
5.
Cancer Gene Ther ; 16(10): 786-93, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19363465

RESUMO

In human Burkitt's Lymphoma (BL) BRG cells, a t(8;14) translocation, placing c-myc near the Emu enhancer of the H chain locus, causes tumor expansion. Earlier, we showed that a peptide nucleic acid complementary to the Emu sequence (PNAEmu), specifically inhibited the expression of translocated c-myc and impaired the growth of BRG cells-induced subcutaneous tumors in mice suffering from severe combined immunodeficiency (SCID). In this study, the therapeutic potential of PNAEmu was evaluated in a systemic mouse model. BRG-BL cells transfected with the luciferase gene were inoculated intravenously into SCID mice resulting in a preferential expansion, similar to the one of human adult patients, in the abdominal cavity, central nervous system and bone marrow. The mice were chronically injected intraperitoneally either with PNAEmu or with control PNA. The treatment was stopped when the control animals developed severe neurological symptoms. As detected both by inspection at necropsy and imaging, overall tumor growth in PNAEmu-treated mice decreased by >80%. Histological and immunohistochemical studies showed, only in PNAEmu-treated mice, a substantially reduced BL cell growth at the major sites of invasion and vast areas of necrosis in the lymphomatous tissues, with concomitant c-myc expression downregulation. Altogether, the data support the therapeutic potential of PNAEmu in human adult BL.


Assuntos
Linfoma de Burkitt/tratamento farmacológico , Ácidos Nucleicos Peptídicos/farmacologia , Animais , Linfoma de Burkitt/genética , Linfoma de Burkitt/metabolismo , Linhagem Celular Tumoral , Transformação Celular Viral , Feminino , Humanos , Luciferases de Vaga-Lume/biossíntese , Luciferases de Vaga-Lume/genética , Medições Luminescentes , Camundongos , Camundongos SCID , Proteínas Proto-Oncogênicas c-myc/biossíntese , Proteínas Proto-Oncogênicas c-myc/genética , Transfecção , Ensaios Antitumorais Modelo de Xenoenxerto
6.
Minerva Urol Nefrol ; 60(1): 65-7, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18427437

RESUMO

Lymphangioma is a rare benign tumor caused by failure in the development of the lymphatic communicating system. The corresponding nomenclature is confusing. In recent years ''renal lymphangiectasia'' is the preferred name. Although this disease may occur in any site of the body, the neck (75%) and axillary area (20%) are the most common sites, and the kidney is occasionally involved. We report a case of lymphangioma communicating with the urinary system in a 61-year-old man diagnosed by CT scan treated with nephrectomy and histological confirmation.


Assuntos
Neoplasias Renais/diagnóstico por imagem , Neoplasias Renais/cirurgia , Linfangioma/diagnóstico por imagem , Linfangioma/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Nefrectomia , Tomografia Computadorizada por Raios X , Resultado do Tratamento
7.
Infection ; 35(3): 134-42, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17565453

RESUMO

The present document contains recommendations for assessment, prevention and treatment of cardiovascular risk for HIV-infected patients. All recommendations were graded according to the strength and quality of the evidence and were voted on by 73 members of the Italian Cardiovascular Risk Guidelines Working Group which includes both experts in HIV/AIDS care and in cardiovascular and metabolic medicine. Since antiretroviral drug exposure represents only one risk factor, continued emphasis on an integrated management is given. This should include prevention and treatment of known cardiovascular risk factors (such as dyslipidaemia, diabetes, insulin resistance, healthy diet, physical activity, avoidance of smoking), but also rational switch of antiretroviral drugs. A rational switch strategy should consider both metabolic and anthropometric disturbances and effectiveness of antiretroviral regimens.


Assuntos
Terapia Antirretroviral de Alta Atividade/efeitos adversos , Doenças Cardiovasculares/etiologia , Infecções por HIV/tratamento farmacológico , Biomarcadores , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Complicações do Diabetes , Interações Medicamentosas , Dislipidemias/complicações , Feminino , Infecções por HIV/complicações , Humanos , Resistência à Insulina , Itália , Masculino , Fatores de Risco
8.
Cancer Gene Ther ; 14(2): 220-6, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17053816

RESUMO

In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Emu enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Emu sequences (PNAEmuwt), specifically blocks the expression of the c-myc oncogene under the Emu enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEmuwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEmuwt before inoculum and chronic intravenous administration of PNAEmuwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEmuwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEmumut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Emu enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.


Assuntos
Linfoma de Burkitt/patologia , Divisão Celular/efeitos dos fármacos , Genes myc , Ácidos Nucleicos Peptídicos/farmacologia , Animais , Sequência de Bases , Imuno-Histoquímica , Camundongos , Camundongos SCID , Transplante de Neoplasias , Ácidos Nucleicos Peptídicos/química , Biossíntese de Proteínas , RNA Mensageiro/genética , Transcrição Gênica
9.
Ann Oncol ; 17 Suppl 7: vii66-7, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16760297

RESUMO

In the past decade the median overall survival of patients with metastatic colorectal cancer has increased from 12 to more than 20 months, mostly due to the new chemotherapeutic agents, irinotecan and oxaliplatin. Most recently, targeted therapies, that inhibit specific cancer pathways and molecules, have shown promising results in the treatment of patients with metastatic colorectal cancer and other solid tumors. One of the most studied targets for anticancer therapy is the epidermal growth factor receptor (EGFR), which is overexpressed in a variety of malignancies. Cetuximab, an anti-EGFR chimeric monoclonal antibody, has shown clinically meaningful antitumor activity in patients with metastatic colorectal cancer in several clinical trials. Efforts of physicians and researchers are currently directed towards the identification of predictive factors (clinical or molecular) of clinical outcome, with the aim of both optimizing the therapeutic index and dealing with increasing costs of these new compounds.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cetuximab , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Receptores ErbB/antagonistas & inibidores , Receptores ErbB/biossíntese , Humanos , Metástase Neoplásica , Resultado do Tratamento
10.
J Exp Clin Cancer Res ; 25(1): 65-72, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16761620

RESUMO

Human mammaglobin (hMAM) has recently been recognized as a breast associated glycoprotein. Although the biological role of hMAM is unknown, it has been previously reported that hMAM gene expression is a marker of low biological and clinical aggressiveness of breast cancer (BC). In this study, 148 cases of BC tissues were investigated for hMAM mRNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR). In order to evaluate its prognostic value, hMAM was correlated with age of patients, type and size of tumor, nodal stage, histologic grade, c-erbB-2 over expression, Ki67 labelling index, estrogen receptor (ER) status and progesterone receptor (PGR) status. Fisher's exact test was used to examine the association between different parameters and hMAM. hMAM was expressed in 138/148 (93%) of BC tissues examined. Among the 10 hMAM negative cases, 8 were invasive ductal carcinomas (microscopically higher G3 grade) and 2 infiltrating lobular carcinomas. We found a significant association (p = 0.020) between absence of hMAM mRNA and G3 histologic grade but not with any other prognostic parameters studied. The present study indicates that lack of hMAM expression is restricted to the BC with G3 grading. Further studies are needed to clarify the biological basis and the clinical significance of our results.


Assuntos
Neoplasias da Mama/metabolismo , Regulação Neoplásica da Expressão Gênica , Proteínas de Neoplasias/biossíntese , Uteroglobina/biossíntese , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/patologia , Linhagem Celular Tumoral , Feminino , Humanos , Antígeno Ki-67/biossíntese , Mamoglobina A , Pessoa de Meia-Idade , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , RNA Mensageiro/metabolismo , Receptores de Progesterona/metabolismo , Uteroglobina/genética , Uteroglobina/metabolismo
11.
G Ital Med Lav Ergon ; 28(1): 115-21, 2006.
Artigo em Italiano | MEDLINE | ID: mdl-16705900

RESUMO

Depleted uranium (DU), a waste product of uranium enrichment, has several civilian and military applications. It was used as armor-piercing ammunition in international conflicts and was claimed to contribute to health problems, known as the Gulf War Syndrome and recently as the Balkan Syndrome. Leukaemia/Limphoma cases among UN soldiers in the Balkans have been related hypothetically to exposure to DU. The investigations published in the scientific literature give no support for this hypothesis. However future follow-up is necessary for evaluation of long-term risk.


Assuntos
Militares , Neoplasias Induzidas por Radiação/etiologia , Síndrome do Golfo Pérsico , Urânio/efeitos adversos , Guerra , Exposição Ambiental/efeitos adversos , Fluorometria , Humanos , Leucemia Induzida por Radiação/diagnóstico , Leucemia Induzida por Radiação/etiologia , Linfoma/diagnóstico , Linfoma/etiologia , Espectrometria de Massas , Neoplasias Induzidas por Radiação/diagnóstico , Síndrome do Golfo Pérsico/diagnóstico , Fatores de Risco , Nações Unidas , Urânio/urina , Iugoslávia
14.
Hernia ; 9(3): 291-3, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15611836

RESUMO

Ureteral hernia is uncommon and usually misdiagnosed. From an anatomic point of view, we can distinguish between two uretero-inguinal hernias: intraperitoneal and extraperitoneal. Ureter inguinal hernias are nearly always indirect. This kind of hernia can include the ureter alone or, frequently, other abdominal sliding organs within the hernia sac (bladder, bowel tracts, etc.). Kidneys and urinary tracts present normal anatomic conformation, although renal ptosis may be found. As of July 2004, 139 cases of ureteral hernia had been described in the literature. Here we report a case of inguino-scrotal herniation of double district ureter and review the current literature to analyze the main clinical characteristics of this pathology and to establish pitfalls.


Assuntos
Hérnia Inguinal/patologia , Escroto/patologia , Ureter/patologia , Diabetes Mellitus Tipo 2/complicações , Hérnia Inguinal/complicações , Hérnia Inguinal/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/complicações , Ureter/anormalidades
16.
Pathologica ; 95(4): 209-13, 2003 Aug.
Artigo em Italiano | MEDLINE | ID: mdl-14577206

RESUMO

In this report, we describe a case of poorly differentiate myoepithelial cell rich carcinoma in with morphological findings of large poligonal nests with festoon-like pattern sometimes showing central necrosis, reminiscent of a comedo-like pattern and numerous mitoses. Immunohistochemical staining shows positive reaction for cytokeratin AE/1, CAM 5.2, 34 beta E12, vimentin, smooth muscle actin, EMA, S100 protein and oncogene cERB.b2 and negative for estrogen, progesterone, GFAP and chromogranin. Moreover, this carcinoma show the expression of the mammaglobin mRNA, a highly specific marker of breast epithelial cells that it is not expressed in all breast carcinoma.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias da Mama/patologia , Carcinoma/patologia , Mioepitelioma/patologia , Proteínas de Neoplasias/genética , RNA Mensageiro/análise , RNA Neoplásico/análise , Uteroglobina/genética , Idoso , Neoplasias da Mama/química , Neoplasias da Mama/genética , Carcinoma/química , Carcinoma/genética , Células Epiteliais/química , Feminino , Humanos , Mamoglobina A , Mioepitelioma/química , Mioepitelioma/genética , Proteínas de Neoplasias/análise , Especificidade de Órgãos
17.
J Chemother ; 15(4): 394-9, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12962369

RESUMO

We evaluated the toxicity and activity of bleomycin, methotrexate and vinorelbine (BMV) combination chemotherapy in cisplatin-pretreated patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) with the aim of identifying a second-line therapy combination and schedule that might offer an improved therapeutic index. BMV (bleomycin 15 I.U., total dose, methotrexate 30 mg/m2, and vinorelbine 30 mg/m2) was administered intravenously every 2 weeks until disease progression, to 26 consecutive patients. Clinical and CT-scan evaluations revealed 7 partial responses (PR) 127%, 95% confidence interval: 9.6%-44.4%], and 13 patients with stable disease (SD) [50%]. The mean progression-free survival for patients who achieved a PR or SD was 6.47 months (range 4-13 months), with 75% of these patients experiencing partial relief of symptoms, mainly pain and dysphagia. BMV, administered second-line in an outpatient setting, has activity similar to that of the taxanes, but with a more acceptable toxicity profile including an absence of alopecia.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Terapia de Salvação , Vimblastina/análogos & derivados , Idoso , Idoso de 80 Anos ou mais , Bleomicina/administração & dosagem , Cisplatino/administração & dosagem , Progressão da Doença , Neoplasias Esofágicas/tratamento farmacológico , Feminino , Humanos , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Indução de Remissão , Análise de Sobrevida , Resultado do Tratamento , Vimblastina/administração & dosagem , Vinorelbina
18.
Nat Genet ; 31(2): 190-4, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11992123

RESUMO

Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of cancer. In the absence of other genetic alterations, this deregulation results in lack of differentiation, hyperproliferation and apoptosis. The pRB protein acts as a transcriptional repressor by targeting the E2F transcription factors, whose functions are required for entry into S phase. Increased E2F activity can induce S phase in quiescent cells--this is a central element of most models for the development of cancer. We show that although E2F1 alone is not sufficient to induce S phase in diploid mouse and human fibroblasts, increased E2F1 activity can result in S-phase entry in diploid fibroblasts in which the p53-mediated G1 checkpoint is suppressed. In addition, we show that E2F1 can induce S phase in primary mouse fibroblasts lacking pRB. These results indicate that, in addition to acting as an E2F-dependent transcriptional repressor, pRB is also required for the cells to retain the G1 checkpoint in response to unprogrammed proliferative signals.


Assuntos
Proteínas de Ciclo Celular , Proteínas de Ligação a DNA , Fase G1/genética , Proteína do Retinoblastoma/fisiologia , Fase S/genética , Fatores de Transcrição/fisiologia , Proteína Supressora de Tumor p53/fisiologia , Animais , Fatores de Transcrição E2F , Fator de Transcrição E2F1 , Fibroblastos/citologia , Fibroblastos/fisiologia , Fase G1/fisiologia , Regulação da Expressão Gênica/fisiologia , Humanos , Camundongos , Fase S/fisiologia , Transdução de Sinais/genética
19.
Curr Opin Genet Dev ; 12(1): 60-6, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11790556

RESUMO

Loss of function of both the p53 pathway and the retinoblastoma protein (pRB) pathway plays a significant role in the development of most human cancers. Loss of pRB results in deregulated cell proliferation and apoptosis, whereas loss of p53 desensitizes cells to checkpoint signals, including apoptosis. In the past two years, mouse genetics and gene expression profiling have led to major advances in our understanding of how the pRB and p53 pathways regulate apoptosis and thus the development of tumours.


Assuntos
Apoptose/fisiologia , Proteínas de Ciclo Celular , Neoplasias/etiologia , Proteínas Repressoras , Proteína do Retinoblastoma/fisiologia , Proteína Supressora de Tumor p53/fisiologia , Animais , Proteínas de Ligação a DNA/fisiologia , Fatores de Transcrição E2F , Perfilação da Expressão Gênica , Genes Supressores de Tumor , Humanos , Proteína 2 Inibidora de Diferenciação , Camundongos , Neoplasias/genética , Neoplasias/metabolismo , Proteína do Retinoblastoma/genética , Fatores de Transcrição/fisiologia , Proteína Supressora de Tumor p53/genética
20.
Blood ; 98(12): 3473-5, 2001 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-11719390

RESUMO

Kaposi sarcoma-associated herpesvirus (KSHV)-related multicentric Castleman disease (MCD) is potentially lethal. Growing evidence indicates that, as in Epstein-Barr virus-driven lymphoproliferative disorders after transplantation, KSHV DNA burden in peripheral blood mononuclear cells (PBMCs) may represent the most accurate marker of disease activity. This report describes a patient with human immunodeficiency virus who was followed up clinically and by quantitative polymerase chain reaction for KSHV DNA sequences in PBMCs for more than 3 years following the diagnosis of KSHV-related MCD. Therapy with the antiherpesvirus agent cidofovir, antihuman interleukin-6 antibody BE-8, antiblastic chemotherapy, and combination antiretroviral agents did not achieve durable clinical or virologic remission of the disease. By contrast, administration of the anti-CD20 monoclonal antibody rituximab was well tolerated and allowed a 14-month remission of clinical symptoms and KSHV viremia. Rituximab should be added to the therapeutic armamentarium for KSHV-related MCD.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antígenos CD20/imunologia , Hiperplasia do Linfonodo Gigante/virologia , Herpesvirus Humano 8 , Indução de Remissão , Sarcoma de Kaposi/virologia , Síndrome da Imunodeficiência Adquirida/complicações , Anticorpos Monoclonais Murinos , DNA Viral/sangue , Feminino , Herpesvirus Humano 8/genética , Humanos , Imunoterapia , Interleucina-6/análise , Interleucina-6/imunologia , Leucócitos Mononucleares/virologia , Linfonodos/química , Linfonodos/virologia , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Rituximab
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA